Humacyte Goodwill and Intangible Assets 2021-2025 | HUMA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Humacyte goodwill and intangible assets from 2021 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Humacyte goodwill and intangible assets from 2021 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$225.3B
Amgen (AMGN)	$164.8B
Gilead Sciences (GILD)	$144.5B
Vertex Pharmaceuticals (VRTX)	$120.6B
Bristol Myers Squibb (BMY)	$98.6B
CSL (CSLLY)	$85.4B
GSK (GSK)	$77.5B
Regeneron Pharmaceuticals (REGN)	$60.8B
Alnylam Pharmaceuticals (ALNY)	$42.9B
Argenex SE (ARGX)	$36.2B
BioNTech SE (BNTX)	$27.7B
Royalty Pharma (RPRX)	$20.6B
Insmed (INSM)	$19.7B
Biogen (BIIB)	$19.3B
Illumina (ILMN)	$17.3B
Genmab (GMAB)	$15B
Genmab (GNMSF)	$15B
Incyte (INCY)	$13.6B
Moderna (MRNA)	$13.2B
Exelixis (EXEL)	$12.4B
QIAGEN (QGEN)	$11.5B
BioMarin Pharmaceutical (BMRN)	$11.3B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.2B
Bio-Techne Corp (TECH)	$9.2B
Exact Sciences (EXAS)	$9.1B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Legend Biotech (LEGN)	$8B
Roivant Sciences (ROIV)	$7.9B